Skip Navigation LinksHome > October 2011 - Volume 21 - Issue 7 > The Role of Hormonal Therapy in Gynecological Cancers-Curren...
Text sizing:
International Journal of Gynecological Cancer:
doi: 10.1097/IGC.0b013e31821d6021

The Role of Hormonal Therapy in Gynecological Cancers-Current Status and Future Directions

Sjoquist, Katrin M. FRACP*†; Martyn, Julie PhD*†; Edmondson, Richard J. MD, MRCOG‡; Friedlander, Michael L. PhD, FRACP†§∥

Collapse Box


Many gynecological cancers, including epithelial and stromal ovarian cancers; endometrial carcinomas; and some gynecological sarcomas, in particular endometrial stromal sarcomas, express estrogen and/ or progesterone receptors. Hormonal therapy, typically progestogens or tamoxifen, is commonly prescribed to patients with potentially hormone-sensitive recurrent or metastatic gynecological cancers with very variable response rates and clinical benefit reported. Aromatase inhibitors are now widely used to treat postmenopausal women with hormone receptor-positive breast cancers as they have greater activity than tamoxifen and are generally better tolerated. The role of aromatase inhibitors in gynecological cancers is uncertain and has not been well studied, although they do appear to be active. The current evidence to support the use of hormonal therapies including aromatase inhibitors in gynecological cancers is reviewed, and the gaps in our knowledge highlighted.

Copyright © 2011 by IGCS and ESGO


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us


For additional oncology content, visit LWW Oncology Journals on Facebook.